No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

Target·Modality

Indication

Stage

Deal Value

(USD mn)

1

1/2

AstraZeneca

Allorion Therapeutics

n/d (Lead)

EGFR L858R 알로스테릭 저해제

NSCLC

전임상

540

2

1/4

Avenzo Therapeutics

Allorion Therapeutics

AVZO-021

CDK2 선택적 억제제

HR+/HER2- 유방암, 

진행성 고형암

1상

1,040

3

1/8

Radiance Biopharma

Biocytogen

Pharmaceuticals

n/d

HER2/TROP2 BsADC

암

n/d

n/d

4

1/8

Janssen Biotech

Simcha Therapeutics

n/d

DR-18 CAR-T

암

n/d

n/d

5

1/10

동아에스티

Eleven Therapeutics

TERA Platform

AI/ML 기반 xRNA 치료제 개발 플랫폼

섬유성 질환

n/d

n/d

6

1/16

EpiVario Inc

Metabomed LTD

MTB-9655

ACSS2 억제제

암

1상

n/d

No.

Date

Acquires

Issuer

주요 파이프라인

금액
(USD mn)

1

1/8

MSD

Harpoon Therapeutics

- (TriTAC®) Tri-Specific T-cell Activating Construct Platform

- (ProTriTAC™) Prodrug concept of TriTAC®

- (HPN328) DLL3 and CD3 targeting, based on TriTAC®/ SCLC(임상1/2상)

- (HPN217) BCMA and CD3 targeting, based on TriTAC®/ Multiple myeloma(임상1/2상)

- (HPN601) EpCAM and CD3 targeting, based on TriTAC®/ Solid tumor(전임상)

680

2

1/8

Novartis

Calypso Biotech

- (CALY-002) αIL-15 mAb / Celiac disease, Eosinophilic esophagitis(임상1상)

425

3

1/8

J&J 

Ambrx Biopharma

- (ARX517) PSMA ADC / mCRPC(임상1/2상)

- (ARX788) HER2 ADC / HER2+ Breast cancer(임상2/3상)

- (ARX305) CD70 ADC / Renal cell carcinoma(임상1상)

2,000

4

1/9

GSK

Aiolos Bio

- (AIO-001) αTSLP mAb / Asthma, Chronic rhinosinusitis(임상2상)

1,400

5

1/15

Orion Group

LegoChem Biosciences

- (LCB14) HER2 ADC / Breast cancer, NSCLC, Solid cancer, CRC, Gastric cancer (임상1~3상)

- (LCB84) TROP2 ADC / Solid tumor(전임상)

415

6

1/23

Sanofi

Inhibrx

- (INBRX-101) A1AT 조절제/ Alpha-1 항트립신 결핍증(AATD)(임상1상)

2,200

7

1/23

NAYA Biosciences

Florida Biotechnologies

- AAV 벡터 유전자치료제 / 레베르 유전성 시신경병증(LHON)(임상1상)

20

8

1/30

Regeneron Pharmaceuticals Inc

2Seventy Bio Inc

- (bbT-369) CD79A and CD20 targeting CAR-T / B-cell lymphoma refractory(임상1/2상)

- (SC-DARIC33) CD33 targeting CAR-T / Refractory acute myeloid leukemia(임상1상)

15